Sai Parenterals Limited announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its OTC Medicines Supply Agreement with one of Australia's leading pharmacy chains. The renewal is structured as a 3-year deal valued at Australian Dollars (AUD) 30 million, equivalent to approximately INR 204 crores based on an exchange rate of 1 AUD = INR 68.52.

The agreement is effective immediately and includes an expanded product portfolio with provisions for continuous growth through new product development and line extensions to be added over its term. The annual value is approximately AUD 10 million per year.

Noumed Pharmaceuticals will manage the full value chain including manufacturing, product sourcing, regulatory compliance, TGA registrations, warehousing, quality assurance, and nationwide distribution. Noumed owns the product registrations and holds the marketing authorization, while the pharmacy chain retails the products under its own consumer brand.

This agreement follows another renewal on 1st July 2026 of a 7.5-year agreement valued at AUD 202 million (approximately INR 1,300 crore). Combined, these agreements bring the Australian OTC contracted supply book to AUD 232 million, equivalent to approximately INR 1,506 crore in aggregate.

Currently, volumes under these agreements are largely sourced from third-party manufacturers, with Noumed earning a distribution margin. The company indicated that as the Adelaide facility commissions and Indian capacity expands, production will progressively move in-house, converting distribution margin into manufacturing margin on the same contracted revenue.

Management commentary from Mr. Anil Kumar Karusala, Chairman and Managing Director, emphasized that these renewals were earned through years of consistent delivery in tightly regulated markets. Mr. Mark Thulborne, Chief Executive Officer of Noumed Pharmaceuticals, noted that the agreement reflects customer confidence in their supply chain capabilities and that local manufacturing at Adelaide will shorten lead times and reduce inventory requirements.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.